Susquehanna International Group
ACTU

Susquehanna International Group’s Actuate Therapeutics ACTU Stock Holding History

Susquehanna International Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,253
Closed -$62.7K – 14350
2025
Q4 		$62.7K Buy
+10,253
New +$70.4K ﹤0.01% 11674
2025
Q2 		– Sell
-47,634
Closed -$322K – 13929
2025
Q1 		$322K Buy
+47,634
New +$382K ﹤0.01% 9908

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group's ACTU Position: Q1 2026 in Review

Susquehanna International Group sold out of Actuate Therapeutics (ACTU) in Q1 2026, closing a stake of 10,253 shares — an estimated $62.7K sold.

Susquehanna International Group first reported a position in ACTU in Q1 2025 and held it in 2 quarters. The position peaked at $322K in Q1 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Susquehanna International Group reported no remaining Actuate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 10,253 Actuate Therapeutics shares in Q1 2026, an estimated $62.7K.
  • Susquehanna International Group first reported a position in Actuate Therapeutics in Q1 2025 and held it in 2 quarters.
  • Susquehanna International Group's Actuate Therapeutics position peaked at $322K in Q1 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.